Full-Year CORE and All-In EPS & Operating Income Improvement
Full year All-In operating income grew 2% and All-In EPS improved 7%, finishing at $2.75. CORE Perrigo operating income increased 7% year-over-year and CORE EPS rose 14% versus prior year (CORE 2025 baseline EPS $2.52).
Project Energize and Supply Chain Benefits
Operational initiatives (Project Energize and supply chain reinvention) delivered approximately $320 million in benefits in 2025, driving improvements in operating income and EPS.
Share Gains and New Distribution Wins
Company reported accelerating market share gains across key categories and regions, securing over $100 million in new distribution and competitive takeaways and strengthened in-store execution.
Innovation Pipeline Expansion
Management stated the innovation pipeline tripled in value versus the prior year, with a large portion of new product value and geographic expansion planned to land in the second half of 2026 (~60%+ of innovation/opportunistic expansion).
CORE 2026 Guidance and Margin Targets
2026 CORE guidance: organic net sales growth of -3.5% to +0.5%; CORE EPS guidance $2.25 to $2.55; CORE gross margin expected 39%–40% and CORE operating margin 15%–16%.
Operational Enhancement Program
New 2-year operational enhancement program expected to deliver annualized pretax savings of $80 million to $100 million (approximately 80% of savings expected in 2026), with estimated one-time costs of $80 million to $90 million and a planned ~7% global workforce reduction.
Supply Stabilization in Infant Formula
Company reported stabilizing supply in Infant Formula with service levels recovered above 90%, even as demand recovery softened and competition increased.
Cash, Leverage and Margin Progress
Ended 2025 with $532 million cash, full-year operating cash flow $239 million (Q4 operating CF $175 million). Net leverage improved from ~5.5x to 4.0x and operating income margin expanded ~230 basis points over the past 2.5 years.
Regulatory and Quality Execution
Operations reported strong compliance with 30+ inspections in 2025 with no critical or major observations and no recalls, highlighting quality assurance strength.